Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases (Q46095927)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 September 2015

Language	Label	Description	Also known as
English	Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases	scientific article published on 25 September 2015

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

0 references

Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

author name string

David I Quinn

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

Primo N Lara

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

language of work or name

0 references

publication date

25 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

The New England Journal of Medicine

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

373

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

19

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

1872-1874

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immune modulation in cancer with antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26406149

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1056/NEJME1511252

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

PMC publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/26406149

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46095927&oldid=2092407304"